✦ LIBER ✦

Safety and pharmacokinetic trial of docetaxel plus anAstragalus-based herbal formula for non-small cell lung cancer patients

✍ Scribed by Barrie R. Cassileth; Naiyer Rizvi; Gary Deng; K. Simon Yeung; Andrew Vickers; Stacey Guillen; Derek Woo; Marci Coleton; Mark G. Kris

Publisher: Springer
Year: 2009
Tongue: English
Weight: 291 KB
Volume: 65
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-1003-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and pharmacokinetic study of do

Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients

✍ Nagio Takigawa; Yoshihiko Segawa; Daizo Kishino; Keiichi Fujiwara; Yoshiyuki Tok 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 212 KB

Phase I/II trial of docetaxel and carbop

Phase I/II trial of docetaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer

✍ Akira Shoji; Takashi Ogura; Kaneo Suzuki; Hiroshi Takahashi; Kenichi Takahashi; 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 67 KB

Phase II trial of gemcitabine and doceta

Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA–IIIA non-small-cell lung cancer

✍ Masafumi Kawamura; Keisuke Eguchi; Yotaro Izumi; Yasushi Yamato; Teruaki Koike; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 280 KB

A pilot study on safety and pharmacokine

A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients

✍ Aminah Jatoi; James R. Jett; Jeff Sloan; Paul Novotny; Joyce Ford; Uma Prabhakar 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 162 KB

Phase II trial of a 75-mg/m2 dose of doc

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

✍ Vincent A. Miller; James R. Rigas; Prudence A. Francis; Stefan C. Grant; Katheri 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 2 views

## Background. A prior Phase I1 study of a 100-mg/m2 dose of docetaxel conducted at the Memorial Sloan-Kettering Cancer Center (New York, NY) demonstrated a 38% response rate with grade 3 or 4 neutropenia in 76% of the patients and a grade 2 or greater rash or infusionrelated reaction in 41% and 3

Phase I trial of non-cytotoxic suramin a

Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

✍ Elaine T. Lam; Jessie L.- S. Au; Gregory A. Otterson; M. Guillaume Wientjes; Lin 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 422 KB